Interactive Brokers Advertisement
Home > Boards > US Listed > Medical - Drugs >

Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

Add KTOV Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 6/26/2017 8:05:21 PM - Followers: 115 - Board type: Free - Posts Today: 1



US Office

1615 Suter’s Lane NW, Washington DC 20007, Tel:  +1-202-965-2215

Israel Office

One Azrieli Center, Round Tower, Tel Aviv 6701101


Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs
that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.

Kitov is developing combination drug products that treat the pain of osteoarthritis without causing cardiovascular problems.
These drugs will not only not need to be labeled with health warnings, but will actually be labeled as reducing the risk of
cardiovascular events. Kitov’s drugs have the potential to improve the health of millions of patients worldwide.
It is expected that physicians will prefer to prescribe them rather than prescribe two separate drugs, to improve their patients’ health and to reduce their own legal exposure.

Kitov is currently focusing two late-stage drugs. Both contain NSAIDs that are widely consumed throughout the world for treating osteoarthritis.
Each of Kitov’s drugs adds to the NSAID a second drug product that reduces hypertension.

KIT-301: Naproxen combined with anti-hypertension. Ready for phase III clinical trial. New Drug Application (NDA) scheduled
for 20-24 months from start of development.
KIT-302: Celecoxib combined with anti-hypertension. Ready for phase III clinical trial. New Drug Application (NDA) scheduled for 2015.

Osteoarthritis, affecting approximately half of all adults over the age of 50, is a degenerative disease of joints that can cause pain and limit mobility.
Exercise and weight control are important therapies for controlling symptoms, but for many patients medication is the next step in pain treatment.
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly used medications for treating osteoarthritis pain.
However, these medications raise blood pressure (hypertension) and thereby increase the risk of heart attacks, strokes, and death.
This has led the US FDA to require including a black box warning in the labeling of all NSAIDs, warning of these increased cardiovascular risks.


Dr. John Paul Waymack – M.D., Sc.D.

Chairman of the Board of Directors and Chief Medical Officer

Dr. Waymack was one of the founders of Kitov Pharmaceuticals and has served as the Chairman of our Board of Directors and Chief Medical Officer since July 2013. Dr. Waymack has over 20 years of experience in the biopharma field. Dr. Waymack is a former academic transplant surgeon and a former FDA medical officer, with over fifteen years of experience in drug development as a consultant to major pharmaceutical companies, including Pfizer, Roche, Pharmacia, Warner Lambert and Searle. During his 10 years of academic career, Dr. Waymack published over 100 scientific essays, mainly in the fields of prostaglandins and immunology. In addition, Dr. Waymack volunteered to the U.S. army, where he was commissioned and served as a Major in the Medical Corp. in the position of Chief of Surgical Research in the U.S. Army’s Institute for Surgical Research. Dr. Waymack was also an associate professor of surgery at the University of Texas Medical Branch and at the University of Medicine and Dentistry of New Jersey.



Dec. 17, 2015 :  Kitov Pharmaceuticals Reports Additional Data from its Phase III Trial on the Beneficial Blood Pressure Effects of KIT-302

November 20, 2015 : Kitov Pharmaceuticals Holdings Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing

October 21, 2015 : Kitov Pharma Announces Completion of Patient Recruitment for the Phase III Clinical Trial for KIT-302


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
KTOV News: Report of Foreign Issuer (6-k) 04:16 PM
KTOV News: Report of Foreign Issuer (6-k) 06/15/2017 04:33:18 PM
KTOV News: Report of Foreign Issuer (6-k) 06/12/2017 04:28:57 PM
KTOV News: Report of Foreign Issuer (6-k) 06/12/2017 06:04:19 AM
KTOV News: Report of Foreign Issuer (6-k) 06/08/2017 04:31:50 PM
News News Alert: Report of Foreign Issuer (6-k) 06/26/2017 04:16:19 PM
#5685   Nice update today,NDA on its way to being filed. tmeier 06/26/17 08:05:20 PM
#5684   We must admit, Management have all a great EM 06/19/17 11:32:24 AM
#5683   I wish they would sell the company.If you tmeier 06/19/17 11:27:39 AM
#5682   Yes and do not forget the recent developments EM 06/19/17 08:19:23 AM
#5681   Also the kidney renal study top line results RBNEWS 06/19/17 06:51:38 AM
#5680   Great summary, thanks. KIT-302 data is rock solid. Plenty EM 06/16/17 08:21:11 PM
#5679   Did not forget - mentioned as last point Amatuer17 06/16/17 08:10:34 PM
#5678   You forgot: CEO under investigation by Israeli authorities. rocketeer357 06/16/17 08:02:37 PM
#5677   Interesting company and here are few details 1. Amatuer17 06/16/17 08:00:33 PM
#5676   RSU fair market value of Equity-based incentive awards EM 06/16/17 08:14:53 AM
#5675   Wish they would just sell instead of partnership tmeier 06/16/17 08:12:02 AM
#5674   Pretty nice new presentation EM 06/16/17 05:58:16 AM
#5673   Company said it planned to file NDA on DavidW2 06/15/17 08:03:25 PM
#5672   Same here. Good luck to you as well! Endorfinaholic 06/12/17 08:21:21 PM
#5671   Agree. See if they come through. RBNEWS 06/12/17 08:19:28 PM
#5670   Been holding for almost a year. Well Endorfinaholic 06/12/17 07:48:22 PM
#5669   Many been here a long time. No need RBNEWS 06/12/17 07:42:47 PM
#5668   I would say no, but anything is possible Endorfinaholic 06/12/17 06:57:07 PM
#5667   Geez I hope it's up. Can it really DrStockonomics 06/12/17 06:54:44 PM
#5666   Lots of filings recently. Getting everything in order Endorfinaholic 06/12/17 06:34:33 PM
#5665   Agree this point. Management must communicate and share EM 05/31/17 09:50:45 AM
#5664   My point is that institutional holdings is very Rymankoly 05/31/17 09:43:36 AM
#5663   What are you trying to say? GHP owns 6,8% EM 05/31/17 09:14:14 AM
#5662   The 6.8% was a payment for Tyrnovo Rymankoly 05/31/17 08:54:14 AM
#5661   Already posted several times and it was in EM 05/31/17 05:42:56 AM
#5660   Link? midastouch017 05/31/17 05:30:03 AM
#5659   Wrong percentage .... - GHP Partners owns 6,8% stake EM 05/31/17 05:28:21 AM
#5658   Institutional and Fund Ownership midastouch017 05/31/17 05:15:26 AM
#5657   My investment style is very different from most tykundegex 05/26/17 03:37:04 PM
#5656   You loaded around $3.5 last year. I understand DavidW2 05/26/17 03:07:54 PM
#5655   The same question could be asked of ANY tykundegex 05/26/17 10:44:44 AM
#5654   But that is the key for whole discussion. DavidW2 05/26/17 10:04:55 AM
#5653   There's a difference .... at 1,80$ trading at EM 05/26/17 03:20:11 AM
#5652   Hey, if your costs is about $1.8 then DavidW2 05/25/17 08:12:21 PM
#5651   Those are question you should have asked yourself EM 05/25/17 06:20:08 PM
#5650   I know everything you talked about. DavidW2 05/25/17 05:38:30 PM
#5649   Lack of DD doesn't allow you to see EM 05/25/17 11:37:16 AM
#5648   The one that successfully applied for and was tykundegex 05/25/17 11:37:04 AM
#5647   Ok shorty! tmeier 05/25/17 11:18:47 AM
#5646   CEO under investigation. That is the management team DavidW2 05/25/17 11:16:42 AM
#5645   "This company never file NDA before, I suspect tykundegex 05/25/17 10:21:31 AM
#5644   I still have some, I had a lot before. DavidW2 05/25/17 10:10:02 AM
#5643   So you are not anymore "very long" EM 05/25/17 10:05:02 AM
#5642   I was very long before. But scandal news DavidW2 05/25/17 09:53:01 AM
#5641   I "suspect" .... I "would" sell .... Where is EM 05/25/17 09:44:50 AM
#5640   LOL. I just want to say, I would DavidW2 05/25/17 09:39:42 AM
#5639   I think only fools short at a bottom tmeier 05/25/17 09:09:19 AM
#5638   I smell their fear .... EM 05/25/17 09:02:26 AM
#5637   Ok tmeier 05/25/17 06:10:09 AM
#5636   Late June? FDA also needs to accept it. DavidW2 05/25/17 02:24:24 AM